Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly 4Q Results | Contract Pharma

What are you searching for?

Sign in
Financial News

Lilly 4Q Results

Mounjaro and Zepbound drive significant growth in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Lilly

Image courtesy of Lilly.

Lilly 

4Q Revenues: $19.3 billion +43%

4Q Earnings: $6.6 billion +50%

FY Revenues: $65.2 billion +45% 

FY Earnings: $20.6 billion +95%

Comments: Growth in the quarter driven by a 46% increase in volume, partially offset by a 5% decrease due to lower realized prices. Key Products revenue grew to $13.8 billion in the quarter, led by Mounjaro and Zepbound. 

Mounjaro sales were $7.4 billion in the quarter, up 110%. Zepbound sales were $4.3 billion, up 123%. Verzenio sales were $1.6 billion, up 3%. Other Key Products include Ebglyss, Inluriyo, Jaypirca, Kisunla, Omvoh.

Talz sales were $1.1 billion in the quarter, up 10%. Trulicity sales were down 17% to $1.0 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics